RxDoctor Payments DataLook up a doctor →

Bobby Shah, MD

Pulmonary Disease · Chesterfield, MONPI 1538340930

Payments from drug & device makers

$256,223in general payments, 2019–2025

Across 1,222 payments — averaging $209.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$177K
  • Sanofi$30K
  • Mylan Specialty L.p.$24K
  • Boehringer Ingelheim$13K
  • AstraZeneca$2K
  • Verona Pharma, Inc.$2K
  • plus $9K from 48 others

What the payments were for

  • Consulting fees$5,6002%
  • Speaking & faculty fees$199,56383%
  • Travel & lodging$14,9796%
  • Food & beverage$20,5519%
  • Education$3190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$256,223 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$271,785
Medicare patients
1,049
Services billed
3,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter901$787,751
OfevNintedanib Esylate52$697,961
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr616$365,012
Breo ElliptaFluticasone/Vilanterol397$201,551
Breztri AerosphereBudesonide/Glycopyr/Formoterol106$108,635
EliquisApixaban82$96,894
Stiolto RespimatTiotropium Br/Olodaterol Hcl102$73,041
Dupixent PenDupilumab17$62,437
XareltoRivaroxaban53$57,336
NucalaMepolizumab13$54,580
AdcircaTadalafil11$45,870
SymbicortBudesonide/Formoterol Fumarate119$38,520
Ambrisentan11$31,350
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate114$27,202
Combivent RespimatIpratropium/Albuterol Sulfate44$25,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta$176,708$1,434,2621,983 claims
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat$12,783$819,758221 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$2,497$154,182242 claims
PfizerEliquis, Abrysvo$258$100,51694 claims
Johnson & JohnsonXarelto$489$57,33653 claims
United Therapeutics CorporationAdcirca$521$45,87011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →